Novartis’ CAR-T cancer drug available on NHS to young people

The chimeric antigen receptor T-cell (CAR-T) drug, also known as tisagenlecleucel, is available for young people with relapsed or refractory B-cell acute lymphoblastic leukaemia through the Cancer Drugs Fund.